Log in
Enquire now
‌

US Patent 9474748 Adjuvant chemotherapy for anaplastic gliomas

Patent 9474748 was granted and assigned to Oklahoma Medical Research Foundation on October, 2016 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Oklahoma Medical Research Foundation
Oklahoma Medical Research Foundation
Current Assignee
Oklahoma Medical Research Foundation
Oklahoma Medical Research Foundation
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
9474748
Patent Inventor Names
Robert A. Floyd0
Rheal A. Towner0
Date of Patent
October 25, 2016
Patent Application Number
14159753
Date Filed
January 21, 2014
Patent Citations Received
‌
US Patent 11660280 Treatment of drug resistant gliomas
0
Patent Primary Examiner
‌
Samira Jean-Louis
Patent abstract

The present invention involves the use of 2,4-disulfonyl phenyl tert-butyl nitrone (2,4-ds-PBN) in the treatment and prevention of gliomas. The 2,4-ds-PBN may be used alone or combined with other traditional chemo- and radiotherapies and surgery, to treat or prevent glioma occurrence, recurrence, spread, growth, metastasis, or vascularization.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 9474748 Adjuvant chemotherapy for anaplastic gliomas

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.